Kan Yonemori
Jikei University School of Medicine(JP)National Cancer Centre Japan(JP)National Cancer Center(US)National Cancer Center Hospital East(JP)Tokyo National Hospital(JP)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Sarcoma Diagnosis and Treatment, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, Protein Degradation and Inhibitors
Most-Cited Works
- → Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study(2017)477 cited
- → Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study(2021)384 cited
- → Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study(2019)366 cited
- → Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer(2024)317 cited
- → Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer(2011)303 cited
- → 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer